Hosted on MSN
GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled
CureVac (NASDAQ:CVAC) announced on Friday that the company and its partner, GSK (NYSE:GSK), are set to receive $740M and other payments, as Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have agreed to ...
Set against a backdrop of barren biotech investment, Vivo Capital has secured $740m to back preclinical and clinical-stage life science companies. The funds will be allocated in the latest cycle of ...
Deal When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. AMD's six-core, twelve-thread Ryzen 5 8500G processor with a built-in Radeon 740M graphics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results